EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Sentinel Lymph Node Biopsy: Is There a Role in Non-Melanoma Skin Cancer? A Systematic Review

Lorenzo Borgognoni, Pietro Susini, Gianni Gerlini, Paola Brandani, Vanni Giannotti, Serena Sestini

Cancers · 23.12.2024 · 16 (24) · 4279

DOI: 10.3390/cancers16244279 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.12.2024. Verfasst von Lorenzo Borgognoni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Plastic and Reconstructive Surgery Unit, Regional Melanoma Referral Center and Melanoma & Skin Cancer Unit, Santa Maria Annunziata Hospital, 50012 Fl…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Sentinel Lymph Node Biopsy (SLNB) aims at identifying clinically occult nodal metastases. It is the standard staging procedure for patients with T1b to T4 primary cutaneous melanoma. Moreover, it is recommended whenever the risk of a positive SLNB is >5%, according to the National Comprehensive Cancer Network Melanoma guidelines. When considering Non-Melanoma Skin Cancer (NMSC), the SLNB could play a role in tumors that mainly spreads via lymphatics, but strong evidence is missing. In this paper, the hot topics and controversies are reviewed; Methods: A PRISMA systematic review was carried out on the PubMed (MEDLINE) library from 2004–2024, searching for studies on SLNB in NMSC; Results: Seventy articles and 6379 patients undergoing SLNB for Squamous Cell Carcinoma (SCC), Merkel Cell Carcinoma (MCC), and Porocarcinoma were included. Overall, the SLNB positivity rate in these NMSCs was 24.4%, with an SNLB detection rate of 97.6%. Specifically, the SLNB positivity rate was 12.3% for high-risk cutaneous SCC, 24.4% for anogenital SCC, 29.3% for MCC, and 30.6% for Porocarcinoma. Most papers concluded that SLNB is safe, feasible, and significant in these malignancies; Conclusions: SLNB should be discussed and offered to every patient with MCC, and it should be discussed and considered in “high risk” SCC and Porocarcinoma for staging and prognostic purposes, aiming to identify a subgroup of patients who may benefit the most from early treatments.

Schlagwörter

Stichwörter der Autor:innen

Merkel Carcinoma and Sentinel Node BiopsyNon-Melanoma Skin Cancer and Sentinel Node BiopsyPorocarcinoma and Sentinel Node BiopsySquamous Cell Carcinoma and Sentinel Node Biopsy

Autor:innen und Institutionen

  • Plastic and Reconstructive Surgery Unit, Regional Melanoma Referral Center and Melanoma & Skin Cancer Unit, Santa Maria Annunziata Hospital, 50012 Florence, Italy.
  • Plastic Surgery Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy.

Zitieren

APA

Borgognoni, L., Susini, P., Gerlini, G., Brandani, P., Giannotti, V., & Sestini, S. (2024). Sentinel Lymph Node Biopsy: Is There a Role in Non-Melanoma Skin Cancer? A Systematic Review. Cancers, 16(24), 4279. https://doi.org/10.3390/cancers16244279

Vancouver

Borgognoni L, Susini P, Gerlini G, Brandani P, Giannotti V, Sestini S. Sentinel Lymph Node Biopsy: Is There a Role in Non-Melanoma Skin Cancer? A Systematic Review. Cancers. 2024;16(24):4279. doi:10.3390/cancers16244279

BibTeX
@article{Borgognoni2024,
  author = {Borgognoni, Lorenzo and Susini, Pietro and Gerlini, Gianni and Brandani, Paola and Giannotti, Vanni and Sestini, Serena},
  title = {Sentinel Lymph Node Biopsy: Is There a Role in Non-Melanoma Skin Cancer? A Systematic Review},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {24},
  pages = {4279},
  doi = {10.3390/cancers16244279}
}
Kostenlos starten →